ANIP (ANI Pharmaceuticals, Inc.) Future Price to Earnings
ANI Pharmaceuticals' bet on skilled technologists and FDA standards ensures high production efficiency. The company's forward P/E ratio visualizes market expectations, where 7.00 reflects the metric's baseline level. Environmental responsibility is manifested in the safe disposal of chemicals, while the brand's pragmatic image is confirmed by supply reliability and the successful revival of niche generics.
Summary analytical data breakdowns for ANI Pharmaceuticals Corp (ANIP)
- current price and projected stock value:
- business market valuation indicators:
- balance sheet equity data:
- debt level and financial liquidity data:
Total Debt to Capital ANI Pharmaceuticals|ANIP - Long-Term Liabilities to Capital|Short-Term Debt to Equity ANI Pharmaceuticals|ANIP - Aggregate Debt Obligations|Debts to Book Capitalization ANI Pharmaceuticals Inc|ANIP - Company Long-Term Debts|Company Short-Term Debt ANI Pharmaceuticals|Quick Ratio anipharmaceuticals.com
- financial results and valuation multiples details:
ANIP - Net Financial Result|Future Profit ANI Pharmaceuticals|ANIP - Company Value to Net Income|Future Price to Earnings ANI Pharma|ANIP - Market Cap to Earnings and Growth Ratio|EV/EBITDA Multiple ANI Pharmaceuticals Inc|ANIP - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) ANI Pharmaceuticals|ANIP - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months anipharmaceuticals.com|ANIP - Earnings per share increase in current year|Net earnings per share growth forecast for next year ANI Pharmaceuticals
- company sales and revenue statistics:
Fundamental valuation:ANI Pharmaceuticals, Inc.
To objectively assess asset quality, it is essential for an investor to compare current market value with projected earnings, which determines the extent to which a business is overvalued or undervalued. By analyzing the expected P/E multiple of ANI Pharmaceuticals (ANIP), you measure the value of future cash flows, which confirms the stability of the company's capitalization driven by consistent demand for its portfolio of niche generics.
Analysis of competing companies
Projected Price to Earnings HLN (Haleon)|KVUE (Kenvue Inc) - Future Price to Earnings Multiple|Future Price to Earnings Verona Pharma Corp VRNA|Jyong Bio (MENS) - Projected Price to Earnings Ratio|LGND: Projected Price to Earnings|amneal.com - Market Cap to Future Earnings Ratio|PRGO: Forward P/E Multiple|Alvotech S.A. - Future Price to Earnings Multiple|LQDA (Liquidia Technologies) - Forward P/E Multiple|Projected Price to Earnings Ratio Galapagos Corp GLPG|Future Price to Earnings MannKind Corporation (MNKD)|AMPH (amphastar.com) - Future Price to Earnings Multiple|Forward P/E Multiple PCRX (Pacira BioSciences, Inc.)|Forward P/E Multiple ARS Pharmaceuticals Inc SPRY|TBPH - Future Price to Earnings|AQST (Aquestive Corp) - Price to Future Earnings Ratio|SCPH: Forward P/E Multiple|TECX - Market Cap to Projected Earnings|Projected Price to Earnings TNXP|SXTC: Future Price to Earnings Multiple|Future Price to Earnings Eupraxia Pharmaceuticals (EPRX)|BHST: Price to Expected Earnings Ratio|Forward P/E Multiple EXOZ (eXoZymes Inc)|Future Price to Earnings Multiple ORMP|Entera Bio Corp - Forward P/E Multiple|HYFT - Forward P/E Multiple|ABVC BioPharma Inc (ABVC) - Future Price to Earnings|Cumberland Corp - Future Price to Earnings Multiple|Future Price to Earnings Quantum BioPharma Ltd|Projected Price to Earnings fibrogen.com (FGEN)|Forward P/E Multiple TELO|Forward P/E Multiple ranitherapeutics.com (RANI)|Forward P/E Multiple SNYR (Synergy CHC)|RLYB - Projected Price to Earnings|Lexaria - Forward P/E Multiple|Projected Price to Earnings Ratio pulmatrix.com|PTHL (ftzy.com.cn) - Projected Price to Earnings|Aptorum Group (APM) - Forward P/E Multiple|Projected Price to Earnings LYRA|IBO (Impact BioMedical, Inc.) - Market Cap to Future Earnings Ratio|Forward P/E Multiple TNFA|Market Cap to Projected Earnings cbdmd.com|Forward P/E Multiple PRFX (PainReform)|CYTO - Projected Price to Earnings|Lipella - Forward P/E Multiple|OPTN - Forward P/E Multiple|Pieris Pharmaceuticals (PIRS) - Future Price to Earnings|PROC (procapsgroup.com) - Future Price to Earnings|Future Price to Earnings Petros Pharmaceuticals, Inc.|Qilian International Holding Group (QLI) - Market Cap to Projected Earnings|Forward P/E Multiple SLRN|Forward P/E Multiple TFF Pharmaceuticals, Inc (TFFP)
